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Abstract
Background: Although acetylsalicylic acid (ASA) is not frequently used as a therapeutic agent in horses, its
metabolite SA is of special interest in equestrianism since it is a natural component of many plants used as horse
feed. This led to the establishment of thresholds by horse sport organizations for SA in urine and plasma. The aim
of this study was to investigate plasma and urine concentrations of salicylic acid (SA) after oral administration of
three different single dosages (12.5 mg/kg, 25 mg/kg and 50 mg/kg) of acetylsalicylic acid (ASA) to eight horses in
a cross-over designed study.
Results: In the 12.5 mg/kg group, SA concentrations in urine peaked 2 h after oral administration (2675 μg/mL);
plasma concentrations peaked at 1.5 h (17 μg/mL). In the 25 mg/kg group, maximum concentrations were detected
after 2 h (urine, 2785 μg/mL) and 1.5 h (plasma, 23 μg/mL). In the 50 mg/kg group, maximum concentrations were
observed after 5 h (urine, 3915 μg/mL) and 1.5 h (plasma, 45 μg/mL). The plasma half-life calculated for SA varied
between 5.0 and 5.7 h. The urine concentration of SA fell below the threshold of 750 μg/mL (set by the International
Equestrian Federation FEI and most of the horseracing authorities) between 7 and 26 h after administration of 12.5 and
25 mg/kg ASA and between 24 and 36 h after administration of 50 mg/kg ASA. For ASA, IC50 were 0.50 μg/mL (COX-1)
and 5.14 μg/mL (COX-2). For salicylic acid, it was not possible to calculate an IC50 for either COX due to insufficient
inhibition of both cyclooxygenases.
Conclusion: The established SA thresholds of 750 μg//mL urine and 6.5 μg/mL plasma appear too generous and are
leaving space for misuse of the anti-inflammatory and analgetic compound ASA in horses.
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Background
Salicylic acid (SA) is one of the oldest nonsteroidal anti-
inflammatory drugs (NSAIDs) and has been used as an
antipyretic agent and in acute rheumatic events in humans
for a long time [1]. Also in veterinary medicine, it has been
administered in cases of joint disease in dogs and horses
[2]. Acetylsalicylic acid (ASA) was synthesized to have the
same effects as SA with an improved gastric and systemic
tolerability profile [3]. After administration, ASA is rapidly
converted to SA [4]. Additionally, ASA is sensitive to
methanol, heat, change of pH and other factors. So, ASA
itself cannot be detected with sufficient accuracy, because
it is dissociated to SA and acetylic acid, even during sample
storage and LC-MS analysis. Even though ASA is not fre-
quently used as a therapeutic agent in horses, its metabol-
ite SA is of special interest in equestrianism since it is a
natural component of many plants used as horse feed, e.g.
alfalfa hay or willow bark. Therefore, SA concentrations
can be found in blood and urine samples of horses after
consumption of any of these plants [5]. This led to the es-
tablishment of thresholds by horse sport organizations for
SA in urine and plasma to avoid positive doping cases due
to accidental feed intake, resulting in false positive. The
International Equestrian Federation (FEI) and most of the
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horseracing authorities (for example in Europe, U.S.A.)
have set SA thresholds at 750 μg/mL in urine and 6.5 μg/
mL in plasma [6]. These threshold levels were based on
several studies [5, 7, 8], in which the average urine concen-
tration of SA was dependent on the horse’s diet and coun-
try of origin. However, the thresholds were established on
a arbitrary statistical basis and not extrapolated from any
irrelevant plasma or urine concentration as proposed by
Toutain and Lassourd [9].
The study presented aimed to investigate average time
intervals elapsed until plasma and urine concentrations
fall below the threshold after oral administration of dif-
ferent dosages of ASA. Recommended ASA dosages for
horses in literature vary between 5 and 100 mg/kg and
from twice daily to every other day [10]. Main indica-
tions are inflammatory processes, pain and fever. In this
cross-over designed study, eight horses received
12.5 mg/kg, 25 mg/kg, and 50 mg/kg ASA orally once
daily. Blood and urine samples were analyzed via HPLC-
MS/MS. Furthermore, to assess the efficacy of salicylates
on COX-1 and COX-2 inhibition in horses, the IC50, i.e.
the drug concentration required to inhibit 50% of COX





The animal study protocol was approved by the regional
administration of the governmental body (LAVES; Lower
Saxony, Germany; 33.9-42502-04-11/0512). Eight stand-
ardbred horses (4 mares, 4 geldings, 12.4 ± 3.2 years old;
656 ± 95 kg body weight) were used in this study. Horses
were housed in stables of Serumwerk Memsen, WDT,
Germany (owner of the horses) with straw bedding and
daily turnout. They were fed a diet free from detectable
SA contamination consisting of hay, grass, beets and
water ad libitum. All horses were healthy on the basis of
a clinical examination prior to the study.
Animal study
Three dosages of ASA were chosen: 12.5 mg/kg, 25 mg/
kg, and 50 mg/kg bodyweight once daily. Horses re-
ceived single oral doses of the ASA powder (Pyrinagil®,
Veyx, Schwarzenborn, Germany) mixed with syrup in
100 mL syringes. The study was conducted in a 4-way,
3-treatment cross-over design with a washout period of
at least 2 weeks. Blood samples were drawn in lithium
heparin tubes at the following timepoints: −24, −21, −18
(blank samples), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12,
14, 16, 24, 36, 48, 72, 96, 120, 144 and 168 h after treat-
ment. Plasma was separated after centrifugation (10 min
at 1400 × g) immediately after withdrawal. Three blank
urine samples (sampled during spontaneous emiction)
were taken from each horse between 24 and 18 h before
treatment. Urine samples were taken at 2, 5, 7, 12, 24,
36, 48, 72, 96, 120, 144, 168 and 192 h after treatment
for each dosage tested; for 50 mg/kg ASA, an additional
sample was taken after 216 h. Both, urine and plasma
samples were stored at −20 °C until analysis (storage
time about 4 weeks).
Quantification of SA in urine and plasma
Initially, it had been planned to measure ASA and SA in
urine and plasma samples. However, this this was not
feasible as ASA turned out to be sensitive to methanol,
heat, change of pH and was continuously dissociated to
SA, even during LC-MS analysis. ASA could therefore
not be detected with sufficient accuracy so that it was
decided to convert all ASA to SA and to measure total
salicylates in plasma and urine by increasing the pH to
13–14. Since SA is the main metabolite of ASA, no
other metabolites such as gentisic or salicyluric acid
were quantified. Quantification of SA was partially based
on methods described previously [11] and accomplished
by an internal standard calibration. SA concentrations
were determined using chromatographic peak area/con-
centration ratios and linear regression analysis to IS area
ratios.
Materials and chemicals
Ammonium acetate, glacial acetic acid, potassium hy-
droxide, sodium dihydrogen phosphate-monohydrate,
di-sodium hydrogen phosphate and methanol (analytical
grade) were obtained from Merck (Darmstadt,
Germany); acetonitrile (HPLC grade) was purchased
from VWR (Darmstadt, Germany). Oasis ® HLB SPE car-
tridges (60 mg, 3 mL) were purchased from Roche
(Mannheim, Germany). Deionised water was of MilliQ
grade. SA and the internal standard D4-SA were ob-
tained from Sigma-Aldrich (Germany) and Toronto Re-
search Chemicals (North York, Canada), respectively.
For standard curves, pooled urine of horses with known
SA concentrations as well as commercially available
equine donor plasma (Sera Laboratories International,
West Sussex, UK) were used.
Plasma sample preparation
For plasma samples, a direct injection method published
by Thomas et al. [12] was modified. To 500 μL Milli-Q-
water and 1 μg of the internal standard D4-SA 500 μl
plasma were added. Samples taken up to 6 h (12.5 and
25 mg/kg) and up to 8 h after ASA administration were
diluted 1:5 in Milli-Q-water before sample preparation.
For protein precipitation, 1.5 mL acetonitrile were added
and gently mixed. After centrifugation (10 min, 3000 U),
20 μL of KOH (5 mol/L) were added to the supernatant
to alkalinize the sample to pH 13–14 for 20 min in order
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to hydrolyze all ASA to SA. To make the pH compatible
with the HPLC column, the sample was adjusted to
pH 1–2 by adding 20 μL HCl (6 mol/L) and centrifuged
again (10 min, 1400 g). 200 μL aliquots were used for
HPLC-MS/MS analysis.
Urine sample preparation
The sample preparation for the quantitative analysis of
SA was performed following the method described by
Schenk et al. [11] and included a solid phase extraction.
Briefly, 2 μg of the internal standard D4-SA were added
to 100 μL of urine and 900 μL of Milli-Q-water. Samples
taken during the first 24 h after treatment were diluted
1:10 in Milli-Q-water (12.5 mg/kg and 25 mg/kg),
whereas samples of the 50 mg/kg group were diluted
1:50. To enforce hydrolysis of any remaining ASA to SA,
the pH was adjusted to 13–14 by addition of 40 μL
KOH (1 mol/l). After 20 min an adjustment to pH 7 was
achieved by addition of 0.2 mL phosphate buffer
(Na2HPO4/NaH2PO4,0.8 mol/l). After centrifugation
(5 min, 500 g), solid phase extraction was performed
with conditioned Oasis® HLB 3 cc (60 mg) extraction
cartridges (Waters corp., Milford, MA, USA). Samples
were then evaporated to dryness in a rotary evaporator
and dried residues dissolved in 200 μL ammonium acet-
ate/acetonitrile (30:20, v/v) for HPLC-MS/MS injection.
Instrumentation-liquid chromatography
The liquid chromatography system comprised an Agilent
Series 1100 LC (Agilent Technologies, Waldbronn,
Germany). Analyte separation (plasma and urine sam-
ples) was achieved with a Nucleodur Pyramid column
(70 × 4 mm, 5 μm particle size) from Macherey-Nagel
(Düren, Germany). For plasma samples, a Gemini C6
Phenyl (4 × 2 mm) guard column was added (Phenom-
enex, Aschaffenburg, Germany). The mobile phase com-
prised ammonium acetate buffer (5 mmol/l ammonium
acetate, 0.1% glacial acid in MilliQ water, pH 3.5; solvent
A) and acetonitrile (solvent B). The following pro-
grammed mobile phase gradient was used for analyte
separation: gradient B 0–100% in 7 min, held for 1 min
at 100% B, reequilibration time at 0% B for 3 min, run
time 11 min. The mobile phase flow rate was 800 μL/
min. The retention time was 5.2 min.
Instrumentation-mass spectrometry
Mass analysis was performed on an API 3200 triple-
quadrupole mass spectrometer (AB Sciex, Darmstadt,
Germany), equipped with an electrospray ionisation
(ESI) interface. Samples were measured in the negative
operation mode at an interface temperature 450 °C with
an ion spray voltage of −4500 V. Collision-induced dis-
sociation with nitrogen was performed at a collision gas
pressure of 2.9 × 10−3 Pa. Diagnostic ions were detected
in the multiple reaction monitoring mode (MRM). The
transition ions monitored for SA were m/z 137→ −93;
m/z 137→ −65; m/z 137→ −41; m/z 137→ −75; those
for d4-SA were m/z 141→ −97; and m/z 141→ −69.
The quantifying ion for urine samples were m/z 137→
−75 (collision energy −38 eV) and m/z 137→ 65 (colli-
sion energy −40 eV) for plasma, respectively. Data acqui-
sition and analysis were accomplished with Analyst®
software (version 1.4.2, AB Sciex).
Method validation
The method was validated according to the guidelines of
the European Horseracing Scientific Liaison Committee
[13]. Validation parameters were selectivity, recovery,
linearity, limit of quantification, limit of detection, ana-
lyte stability, precision, and accuracy. The calibration
range was 5 to 250 μg/mL (urine samples) and 0.3 to
20 μg/mL (plasma samples).
Recovery was only calculated for urine, as plasma con-
centrations were determined by direct injection. To
prove stability, quality control samples were stored
under the same conditions as post administration sam-
ples for a minimum of 4 weeks.
Pharmacokinetic analysis
Pharmacokinetic parameters of SA in plasma were cal-
culated with WinNonlin® 5.3 (Pharsight, Mountain View,
USA), using a non-compartmental analysis. Because the
SA concentration in plasma samples of untreated horses
was below of the LLOQ (0.3 μg/ml), the absolute values
were used for the PK calculation. The following informa-
tion was obtained: Cmax, Tmax, clearance (Cl/F), MRT,
elimination rate constant, half-life λz and AUClast.
Pharmacodynamic study, COX-1 assay, COX-2 assay
Materials and chemicals
Compounds used for the pharmacodynamic study were
ASA and SA (all Sigma Aldrich, Munich, Germany).
Substances were diluted in dimethyl sulfoxide (DMSO;
Merck, Darmstadt, Germany) in concentrations from 0.1
to 1000 mmol/L. LPS (Escherichia coli O111:B4) used
for COX-2 assays was obtained from Sigma Aldrich,
Munich, Germany. Samples were analyzed for thromb-
oxane B2 and prostaglandin E2 concentrations using en-
zyme immunoassays (Cayman Chemicals, Ann Arbor,
MI, USA).
Animals and study design
According to Brideau et al. [14] and McCann et al. [15],
the COX-1 inhibition was quantified by each substance’s
ability to inhibit the formation of clot-induced Thromb-
oxane B2 (TXB2) using blood from six clinically healthy
warmblood horses (five mares and one gelding). To
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assess COX-2 inhibition, LPS-induced Prostaglandin E2
(PGE2) production was measured.
In vitro assay
For the COX-1 assay, blood was drawn by jugular
venipuncture into vacuum tubes containing no anti-
coagulant (Greiner bio-one, Frickenhausen, Germany).
Immediately afterwards, blood aliquots (500 μL) were
transferred into polypropylene tubes prepared with 5 μL
of vehicle (DMSO), ASA or SA at final concentrations of
0.1, 1, 10, 100, or 1000 μmol/L. After mixing, tubes were
incubated for 1 h at 37 °C to allow the blood to clot.
Samples were then centrifuged at 4 °C and 2000 × g for
10 min. Supernatants were stored at −80 °C until
analysis.
For the COX-2 assay, plasma was drawn in lithium
heparin tubes (Vacutainer, BD, Heidelberg, Germany).
Aliquots of 500 μL were transferred into polypropyl-
ene tubes and preincubated with 10 μL LPS dissolved
in phosphate buffered saline (100 μg/mL). After
5 min of incubation at 37 °C, ASA or SA were added.
A further incubation period of 24 h at 37 °C
followed. One aliquot of blood was not incubated
with LPS and used as control. Samples were centri-
fuged as described above and supernatants stored at
−80 °C. A pre-incubation with a COX-1 inhibitor was
not included in the performed COX-2 assay. After
thawing, samples were diluted in EIA buffer (1:10)
and used directly for the immunoassays without a
preliminary extraction. The immunoassays were per-
formed according to the manufacturer’s instructions
(Dynatech Microplate Reader, Dynatech Laboratories,
Denkendorf, Germany).
Statistical analysis
Data were analyzed with a commercially available soft-
ware program (GraphPad Prism 5.03 software; GraphPad
Software, Inc., La Jolla, CA, USA) by use of a one-way-
repeated measures analysis of variance followed by the
Bonferroni post hoc test. Values of P < 0.05 were consid-
ered statistically significant. The concentration leading
to a 50% inhibition of COX activity (IC50) was calculated
with WinNonlin® Professional Edition, Version 5.3, In-
hibitory Effect Sigmoid Imax Model (Pharsight, Moun-
tain View, USA).). The vehicle control was used as
baseline (0% inhibition).
Results
Validation of the analytical method
Identification of SA was ensured by its specific retention
time and four characteristic ion transitions. As no SA
free horse urine and plasma was available, traces of SA
could be detected in each sample. Nevertheless, the SA
Table 1 Precision and accuracy of the analytical method,




(%) (n = 6 per
conc.)
Interday precision
(%) (n = 18 per
conc.)
Accuracy (%)
(n = 6 per
conc.)
Plasma
1 4.6 10.3 2.3
5 4.8 1.1 4.8
10 3.1 3.4 1.6
Urine
10 5.1 13.0 6.3
50 3.4 4.5 5.1
200 8.8 3.2 2.2
Fig. 1 Mean values (± S.D.) of SA concentrations in plasma of horses after a single oral dose of 12.5 mg/kg BW (n = 8). Black line = values > LLOQ.
Grey line = values < LLOQ. Dotted line = LLOQ. Dashed line = threshold concentration (FEI)
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concentrations were mostly below the LLOQ and could
easily be discriminated from the spiked samples. Plasma
and urine samples spiked with SA that had been stored
under the same conditions as the post administration
samples, storage at −20 °C for four weeks did not show
any significant difference in analyte degeneration (one-
tailed T-test). Recovery was calculated to be 51% in
urine.
Calibration curves were found linear in plasma and
urine relating to the specified concentration ranges. The
LLOD was estimated at 1 μg/mL for urine and 0.1 μg/
mL for plasma. The LLOQ was determined at 5 μg/mL
for urine and 0.3 μg/mL for plasma. Summary results for
precision and accuracy are listed in Table 1.
Plasma and urine concentrations of SA after oral ASA
administration
12.5 mg/kg ASA: Maximum plasma concentrations
(Cmax)between 14.5 and 26.9 μg/mL were measured
0.5 h to 1.5 h after administration of ASA. Only in
one horse Cmax was reached eight hours after treat-
ment. Plasma concentrations fell below the set thresh-
old of 6.5 μg/mL between 6 and 16 h after treatment.
Basal SA levels were measured 36 to 48 h after treat-
ment (Fig. 1). In urine, maximum SA concentrations
were achieved between 2 and 7 h after administration
of ASA, with results varying between 699 and
10200 μg/mL. Values fell below the threshold of
750 μg/mL between 7 and 26 h after administration.
Fig. 2 Mean values (± S.D.) of SA concentrations in urine of horses after a single oral dose of 12.5 mg/kg BW (n = 8). Black line = values > LLOQ.
Grey line = values < LLOQ. Dotted line = LLOQ. Dashed line = threshold concentration (FEI)
Fig. 3 Mean values (± S.D.) of SA concentrations in plasma of horses after a single oral Black line = values > LLOQ. Grey line = values < LLOQ.
Dotted line = LLOQ. Dashed line = threshold concentration (FEI)dose of 25.0 mg/kg BW (n = 8)
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One horse did not exceed the urine threshold SA at
all (Fig. 2).
25 mg/kg ASA: Cmax was reached between 0.5 and 6 h
after administrartion (19.1 to 37.8 μg/mL), while plasma
concentrations dropped below the threshold of 6.5 μg/
mL SA between 12 and 24 h. Between 36 and 48 h after
treatment basal levels were reached in all horses (Fig. 3).
All horses showed the highest urinary excretion of SA
between 2 and 5 h after treatment, with values from
1550 to 7640 μg/mL SA. Between 7 and 24 h after ad-
ministration, all horses featured urine SA levels below
the threshold (Fig. 4).
50 mg/kg ASA: Plasma SA levels peaked between 1
and 6 h after administration (35.1 to 62.7 μg/mL).
Plasma levels fell below the threshold at 12 h (n = 2),
14 h (n = 1), 24 h (n = 3) and 36 h (n = 2) after adminis-
tration. Basal levels could be observed again between 36
and 48 h after administration (Fig. 5). Peak urine SA
concentrations were measured between 2 and 7 h (2810
to 9640 μg/mL). Values fell below the threshold between
12 and 36 h (Fig. 6).
A plasma clearance (Cl/F) of 82.2 mL∙h/kg, resulting
in a calculated half-life of 5.2 h (12.5 mg/kg), 97.1 mL∙h/
kg with a half-life of 5.0 h (25 mg/kg), and 114.0 mL∙h/
Fig. 4 Mean values (± S.D.) of SA concentrations in urine of horses after a single oral dose of 25.0 mg/kg BW (n = 8). Black line = values > LLOQ.
Grey line = values < LLOQ. Dotted line = LLOQ. Dashed line = threshold concentration (FEI)
Fig. 5 Mean values (± S.D.) of SA concentrations in plasma of horses after a single oral dose of 50.0 mg/kg BW (n = 8). Black line = values > LLOQ.
Grey line = values < LLOQ. Dotted line = LLOQ. Dashed line = threshold concentration (FEI)
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kg with a half-life of 5.7 h (50 mg/kg) were calculated
(Table 2). The MRT varied between 7.26 and 8.39 h.
Pharmacodynamic study
In order to determine IC50 values, the inhibition of
COX-1 and COX-2 activity was plotted against different
concentrations of ASA (Table 3 and Fig. 7). The vehicle
control was used as the baseline (0% inhibition). The
IC50 of ASA was 1.68 μmol/L (0.50 μg/mL, COX-1) and
17.02 μmol/L (5.14 μg/mL, COX-2), respectively. No
IC50 could be calculated for SA because of an insuffi-
cient COX-Inhibition (IC50 > 100 μmol/L (COX-1) and >
1000 μmol/L (Cox-2)).
Discussion
A method for the quantitative analysis of SA in horse
urine and plasma has been developed and validated. Be-
cause of the distinctive instability of ASA during the
whole process of sample storage, preparation and ana-
lysis, it was decided to convert ASA completely to SA.
Thus the origin of analysed SA values may be caused by
a medication with SA or ASA which is metabolized to
SA as well as by SA as a feeding component of plant ori-
gin (alfalfa hay, willow bark). With a LLOD (LLOQ) of
0.1 μg/mL (0.3 μg/mL) plasma the method is sensitive
enough to detect an ASA administration, because mean
population values of SA were reported to be about
0.23 μg/mL. The LLOD (LLOQ) for urine was deter-
mined to be 1 (5) μg/mL which is adequate considering
the high mean population value of 27.3 μg/mL [11]. The
SA concentration in plasma and urine samples (blanks)
of the horses used in the described study was less than
0.3 μg/mL plasma and between <5 and 51 μg/mL urine.
According to our data, ASA inhibits COX-1 more po-
tently than COX-2, with IC50 values of 1.68 μmol/L and
17.02 μmol/L, respectively. This finding is supported by
the fact that ASA is known to only inhibit COX-1 irre-
versibly [16, 17]. The IC50 values calculated for ASA
confirm results from other non-equine where ASA IC50
values from 1.67 to 4.45 μmol/L for COX-1 and from
5.34 to 15.9 μmol/L for COX-2 were described [18–21].
On the contrary, Vane and Botting [22] calculated an
Fig. 6 Mean values (± S.D.) of SA concentrations in urine of horses after a single oral dose of 50.0 mg/kg BW (n = 8). Black line = values > LLOQ.
Grey line = values < LLOQ. Dotted line = LLOQ. Dashed line = threshold concentration (FEI)
Table 2 Plasma SA pharmacokinetics data after oral
administration of ASA (12.5, 25.0, 50.0 mg/kg) to horses, mean ±
S.D. of eight horses per treatment
Parameter Units 12.5 mg/kg 25.0 mg/kg 50.0 mg/kg
Cmax μg/ml 19.75 ± 5.22 30.06 ± 7.44 51.66 ± 11.27
Tmax h 2.0 ± 2.5 2.5 ± 2.3 2.2 ± 1.7
CI/F ml/h/kg 82.2 ± 18.4 97.1 ± 19.9 114.0 ± 31.9
AUClast h x μg/ml 154.9 ± 31.8 264.9 ± 63.2 457.1 ± 114.8
λZ 1/h 0.145 ± 0.040 0.148 ± 0.041 0.145 ± 0.061
λZ T½ h 5.1 ± 1.4 5.0 ± 1.3 5.7 ± 2.8
MRT h 7.26 ± 2.13 7.81 ± 1.70 8.39 ± 3.67
Table 3 Inhibition of COX-1 and COX-2 activity (%) by ASA and SA;
calculated based on in vitro assays (mean ± S.D. of experiments with




COX I COX II COX I COX II
0.1 9.1 ± 3.6 9.8 ± 4.6 19.6 ± 9.5 4.7 ± 2.3
1.0 30.8 ± 16.0 12.6 ± 8.3 13.0 ± 5.7 15.3 ± 9.3
10.0 87.0 ± 11.5 37.9 ± 29.3 22.8 ± 10.0 10.3 ± 3.4
100.0 93.6 ± 10.3 60.9 ± 23.4 32.2 ± 21.1 –4.7 ± 3.2
1000.0 92.7 ± 12.9 75.7 ± 32.7 65.8 ± 28.4 26.8 ± 11.3
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ASA IC50 of 278 μmol/L for COX-2. SA did not inhibit
either COX effectively enough to calculate an IC50 value
for the concentrations used in this study (up to
1000 μmol/L). Similar findings have been reported in
other studies [18, 19, 21]. However, since SA does have a
clinically proven effect [23] there has to be another
mode of action. An action trough NF-κB or gentisic acid
is just mentioned, but no specific role of these factors
has been proposed to explain the anti-inflammatory ac-
tivity of SA [21, 24].
In doping control the international threshold for SA in
plasma is 6.5 μg/mL. This means that a SA confirmation
may only be reported as “positive” if the detected con-
centration is above this limit. A SA concentration above
this threshold can not be explained by SA as a feeding
component. Measuring SA concentrations below the
threshold level, it remains unclear if the measured SA
concentration is caused by an ASA or SA medication or
by SA as a feeding component [5, 11]. The presented ex-
cretion study should give evidence in how far this thresh-
old is exceeded after a therapeutic medication of ASA.
The threshold was exceeded by 30 min and eight 8 h
following oral administration of 25 and 50 mg/kg ASA,
respectively. Twenty-four hours after administration of
25 mg/kg and thirty-six hours after administration of
50 mg/kg plasma concentrations of all horses were
below the threshold again. The lower dosage of 12.5 mg/
kg which may be used because of the antithrombotic ef-
fects of ASA, led to “positive” concentrations for 12 h
after administration. Thus the detection period of an
ASA administration in a blood sample is rather short.
The detection of an ASA medication is even more dif-
ficult in urine samples when applying the urine thresh-
old of 750 μg/mL. Concentrations higher than this level
were only detected for 24 h after the 50 mg/kg and for
12 h after administration of the 25 or 12.5 mg/kg dose.
After administration of 12.5 mg/kg one horse did not
exceed the threshold at all.
As the detection period of an ASA medication (time
of SA above the threshold) is less than one day in almost
all horses of our study, it has to be discussed whether its
therapeutic effect can be controlled adequately with the
existing rules.
Broome et al. [4] described a rapid decline of the ASA
concentration after intravenous administration of
20 mg/kg ASA to horses. The ASA concentration was
below 0.1 μg/mL after four hours [4]. Comparing the
ASA concentrations measured by Broome et al. (2003)
Fig. 7 Inhibition of COX-1 (black line) and COX-2 (dashed line) by ASA as a result of in vitro assays performed with equine blood; mean ± S.D. of
6 single experiments
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with the IC50 values calculated in the described study, it
can be concluded that a COX-1 inhibitory effect may be
reached for a period of about 3 to 4 h. A COX-2 inhib-
ition should be expected for only 1.5 h. There are hints
that salicylates accumulate in synovial fluid after sys-
temic administration, as demonstrated in vitro by Friebe
et al. [25] who simulated a systemic ASA treatment with
20 mg/kg I.V. in the isolated perfused equine distal limb.
Extrapolated from synovial fluid concentrations mea-
sured in vitro, a COX-1 inhibitory effect can be expected
in the joint for about 6 to 8 h (COX-1) and 2 h (COX-
2). The results of the in vitro and in vivo studies [26] in-
dicate that even if SA values in plasma and urine fall
below the thresholds, one cannot exclude any thera-
peutic effect, especially since NSAIDs are generally
known to accumulate in inflammatory exudate [27].
Conclusion
The established SA thresholds of 750 μg//mL urine and
6.5 μg/mL plasma appear too generous and are leaving
space for misuse of the anti-inflammatory and analgetic
compound ASA especially for countries where horse
feed is not naturally rich in salicylates.
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